Phase 2 N=2 Orlistat for the Treatment of Type I Hyperlipoproteinemia
Hyperlipoproteinemia Type I · Hypertriglyceridemia
Primary: Fasting Serum Triglycerides — 705; 1827; 1511; 1007 mg/dL
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=90 PERIODONTAL DISEASE AND HYPERLIPIDEMIA
Hyperlipidemia, Periodontitis, Gingivitis
Primary: Gingival Crevicular Fluid Level of Malondialdehyde (MDA) as a Marker of Lipid Oxidation. — 144.09; 298.52; 802.09; 139.50 pg/ml
N/A N=2,196 Study of Lipid Control in Hyperlipidemic Participants (MK-0653-179)
Dyslipidemia
Primary: Percentage of Participants Achieving Target Lipid Values — 46.8 Percentage of participants
N/A N=514 Effect of Statins on Lipid Levels Following the First Acute Coronary Event (MK-0000-204)
Dyslipidemias · Hypercholesterolemia · Hypertriglyceridemia
Primary: Total Cholesterol (TC) Levels at First Acute Coronary Event — 163.5 mg/dL
Phase 4 N=57 Extended Release Niacin and Fenofibrate for the Treatment of Atherogenic Dyslipidemia in Obese Females
Atherogenic Dyslipidemia · Obesity Associated Disorder
Primary: Changes Serum Triglyceride Levels — 223.1; 241.2; 227.0; 267.2 mg/dl — p=0.0001
Phase 2 N=220 Study of Atorvastatin/Fenofibrate (LCP-AtorFen) Combination Therapy in Dyslipidemia
Dyslipidemia
Primary: Percent Changes From Baseline to End-of-treatment in Non-HDL Cholesterol, HDL Cholesterol, and Triglycerides by LCP-AtorFen Versus Atorvastatin Monotherapy — -44.8…
Phase 4 N=14 Effects of PCSK9 Inhibition by Evolocumab on Postprandial Lipid Metabolism in Type 2 Diabetes
Type 2 Diabetes Mellitus
Primary: Mean ApoB Concentration Before and After Evolocumab — 75.9; 35.3 mg/dL — p=<0.001
N/A N=687 Study On Liprimar (Atorvastatin) In Patients With Coronary Heart Disease (CHD) And High Risk Of Cardiovascular Complications
Cardiovascular Diseases · Coronary Artery Disease
Primary: Percentage of Participants Achieving LDL Level Less Than or Equal to (≤) 100 mg/dL at the 6 Month Visit — 51.52 percentage of participants
Phase 4 N=70 Telephone Based Management of Hyperlipidemia
Hyperlipidemia
Primary: LDL Level Change From Baseline — -63.4; -54.6 mg/dl — p=0.391
Phase 2 N=59 LIPIDS-P Trial Phase I/II Trial
Sepsis, Severe · Septic Shock
Primary: Phase II - Primary Outcome - Change in Total Cholesterol (48 Hours - Enrollment) — 9; -10; 4; 2 mg/dL
N/A N=1,049 LIpid Lowering With Highly Potent Statins in Hyperlipidaemia With Type 2 Diabetes patiENts
Hypercholesterolemia With Concomitant Type 2 Diabetes
Primary: Percent Change in Non-high-density Lipoprotein Cholesterol (HDL-C) Level — -31.3; -32.8 Percent change
Phase 3 N=1,216 Study of Extended Release Niacin/Laropiprant on Lipids (0524A-067)
Primary Hypercholesterolemia · Mixed Dyslipidemia
Primary: Percent Change From Baseline in Low Density Lipoprotein Cholesterol at Week 12 — -10.0; -5.5 Percent — p=0.006
N/A N=17 Leptin for Abnormal Lipid Kinetics in HIV Lipodystrophy Syndrome
HIV Lipodystrophy
Primary: Rate of Total Lipolysis — 0.649; 0.767 mmol FFA/kg/h
Phase 4 N=97 Effect of Crestor (Rosuvastatin) on Lipid Levels in Patients With Metabolic Syndrome
Metabolic Syndrome
Primary: Basal HDL-cholesterol Level — 39.5 mg/dL
Phase 2 N=20 A Trial of Lipitor (Atorvastatin) for the Treatment of Polycystic Ovary Syndrome (PCOS) in Women With Elevated Low-density Lipoprotein (LDL) Cholesterol
Polycystic Ovary Syndrome
Primary: Brachial Artery Flow-mediated Dilation (FMD) — 12.0; 9.8; 10.4; 10.2 % change in brachial artery diameter — p=0.58
Phase 3 N=36 Effects of Sitagliptin on Postprandial Lipemia in Men With Type 2 Diabetes
Diabetes Mellitus · Postprandial Lipemia
Primary: Measurement of the Area Under the Curve of Plasma Triglycerides (TG) Levels During Postprandial Period (Time 0,2,4,6,8 Hours) — 30.0; 27.1 mmol*h/L
Phase 2 N=398 A Study of LY2484595 in Patients With High LDL-C or Low HDL-C
Dyslipidemia
Primary: Percent Change From Baseline to 12 Weeks Endpoint in High Density Lipoprotein Cholesterol (HDL-C) With LY2484595 in Combination With Atorvastatin and Atorvastatin…
Phase 2 N=107 A Phase II Clinical Study of SB-480848 in Dyslipidemic Patients
Atherosclerosis
Primary: Change From Baseline to Week 4 in Plasma Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Activity — 0.961; 0.494; 0.404; 0.313 Log(millimole per milliliter per minute)…
Phase 4 N=506 A Study to Evaluate Fenofibrate Combination With Statin in Chinese Patients With Dyslipidemic
Dyslipidemias · Cardiovascular Diseases · Hypertriglyceridemia
Primary: Percentage of Triglyceride (TG) Change — -38.12 percentage of TG change
Phase 3 N=2,414 MK-0524B Lipid Study (MK-0524B-063)
Primary Hypercholesterolemia · Mixed Dyslipidemia
Primary: Percentage Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) — -44.6; -46.9; -48.9; -50.4 Percentage Change
Phase 2 N=205 A Study of LY3561774 in Participants With Mixed Dyslipidemia
Dyslipidemias · Lipid Metabolism Disorders · Metabolic Diseases
Primary: Percent Change From Baseline for Apolipoprotein B (ApoB) at Day 180 — -11.6; -14.1; -24.3; -19.0 Percent change — p=0.691
Phase 3 N=89 Effects on Lipoprotein Metabolism From PCSK9 Inhibition Utilizing a Monoclonal Antibody
Primary Hyperlipidemia and Mixed Dyslipidemia
Primary: Percent Change From Baseline in Low-density Lipoprotein (LDL) Apolipoprotein B-100 Fractional Catabolic Rate (FCR) — -5.07; 74.13; 83.70; 310.48 percent change — p=0.018
Phase 3 N=23 Fenofibrate Treatment in SCI
Spinal Cord Injury · Dyslipidemia
Primary: Triglyceride Concentration (Percent Change From Baseline) — -40; -2 percent change from baseline
Phase 4 N=53 Exploratory Study of the Effects of Omega-3-acid Ethyl Esters on the Lipid and Lipoprotein Profile in the Blood
Hyperlipidemia
Primary: Percent Changes From Baseline in Concentration of Major 4 Lipid Constituents in Small Dense Low Density Lipoprotein (sdLDL) Fraction — -6.50; 5.05; -12.35; 4.64 Percent…
Phase 4 N=32 Free Fatty Acid-Induced Hypertension in Obese Subjects With Type 2 Diabetes
Type 2 Diabetes · Hypertension
Primary: Changes in Systolic Blood Pressure During Initial Intralipid Infusion — 23; 13 mmHg
Phase 2 N=619 Phase 2 Dose-Ranging Efficacy and Safety Trial of SCH 900271 in Participants With Primary Hypercholesterolemia or Mixed Hyperlipidemia (P05675)
Primary Hypercholesterolemia · Mixed Hyperlipidemia
Primary: Change From Baseline in Direct LDL-C at Week 8 — -2.0; -1.5; -4.2; 0.2 Percent change — p=0.06
N/A N=2,596 Pragmatic Trial of Messaging to Providers About Treatment of Hyperlipidemia (PROMPT-LIPID)
High Risk Atherosclerotic Cardiovascular Disease
Primary: Proportion of Patients With Intensification of Lipid Lowering Therapy — 159; 142 Participants
Phase 3 N=1,143 Ezetimibe/Simvastatin in Patients With Metabolic Syndrome (0653A-107)(COMPLETED)
Hypercholesterolemia · Metabolic Syndrome
Primary: Percent Change From Baseline in Low Density Lipoprotein (LDL-C) at Week 6 — -36.5; -49.6; -39.4; -53.9 Percent Change — p=<0.001
Phase 3 N=140 12-Month, Open-Label, Extension Study of LCP-AtorFen in Dyslipidemia
Dyslipidemia
Primary: Change in Non-HDL Cholesterol, HDL Cholesterol, TG Levels From Baseline to End of Treatment — -48.2; -43.6; -42.0; 2.6 percent change
Phase 2 N=4 Study of AKCEA-ANGPTL3-LRx (ISIS 703802) in Participants With Familial Partial Lipodystrophy (FPL)
Familial Partial Lipodystrophy
Primary: Percent Change From Baseline in Fasting Triglycerides Levels at End of the Treatment (Week 27) — -59.9 percent change